Bruker Corp. has announced its financial numbers for 2015, with a revenue decline of 10.2 percent to $1.62 billion, compared to 2014’s $1.81 billion. However, its generally accepted accounting principle (GAAP) earnings per share (EPS) grew 82 percent year-over-year to $0.60. Non-GAAP EPS grew by 19 percent to $0.89. The non-GAAP operating margin increased 310 basis points to 13.3 percent, while free clash flow more than doubled to $195 million. “During 2015, we increased our non-GAAP operating margin by more than 300 basis points, we more than doubled our free cash flow and our return on invested capital reached 21.8 percent, despite currency headwinds and weak demand in some of our markets,” said Dr. Frank Laukien, president and CEO of Bruker. “Our three-year transformation has enabled us to strengthen our portfolio, lower our fixed costs, reduce our working capital, reinvest in profitable growth opportunities and improve our processes and systems.” Excluding a 0.6 percent net negative effect from acquisitions and divestitures and a 7.8 percent negative effect from changes in foreign exchange rates, Bruker reported 2.5 percent year-over-year organic revenue growth for the fourth quarter of 2015. “As we look ahead to 2016, we believe we can further improve our profitability by strengthening our commercial practices, implementing lean manufacturing and expanding our outsourcing programs,” Laukien said. “We also will continue to invest in new products and expand into adjacent markets that we believe will generate profitable revenue growth in the future. With a stronger foundation now in place, we expect to deliver gradually accelerating organic revenue growth, further margin increases, and improvements in our working capital ratio in 2016.” Bruker is a manufacturer of analytical and medical instruments for the life sciences, molecular research, microscopy, nanoanalysis and industrial fields.